Idorsia has become the first drugmaker in the EU to claim approval for a drug for chronic insomnia in the dual orexin receptor antagonist class, ahead of rival drugs from Merck & Co and
Swiss biotech Idorsia has claimed FDA approval for its first product – insomnia treatment Quviviq – setting up a market challenge to class rivals from Merck & Co and Eisai.
Eisai has launched its insomnia drug Dayvigo in Japan, the second in a new class of medicines after Merck & Co’s Belsomra, which made its debut there in 2014.
Cancer Research UK (CRUK) has said it will award £123 million ($150 million) in funding over the next seven years to Scotland’s Beatson Institute, which will be renamed th
To improve trial recruitment, engagement, and retention, and to increase the likelihood that trials reflect what matters most to patients, regulatory authorities increasingly point to metho